Fast Five Quiz: COVID-19 Vaccines

Glenn Wortmann, MD


August 02, 2022

A protein-based COVID-19 vaccine is currently used in more than 40 countries in individuals older than 18 years and has been approved by European Medicines Agency for use in individuals aged 12 years and older. The World Health Organization suggests that it can be offered to patients with previous SARS-CoV-2 infection; however, it should not be given to patients with acute illness, including those with a body temperature of 38.5 °C (101.3 °F). Polyethylene glycol (PEG), an ingredient in mRNA vaccines, is not present in the protein-based vaccine. Thus, it is safe for use in patients with PEG allergy. The current recommended dosing regimen is two doses administered 3-8 weeks apart.

Learn more about COVID-19 vaccines.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.